Matthias Ocker

Head of Experimental Medicine

Germany

Research Interests

Explore related searches

Professors in Germany Professors in Cancer Biology Cancer Biology professors in Germany

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Matthias Ocker is the Head of Experimental Medicine at Tacalyx in Germany. His research focuses on drug discovery and treatment strategies for biliary tract cancer and hepatocellular carcinoma, as evidenced by his recent publications on preclinical models, ferroptosis, and immunotherapy approaches. He explores patient selection criteria in FGFR inhibitor trials and examines mechanisms of chemoresistance in the context of targeted therapies.

Articles (11)

Year:

2025

Year:

2024

Year:

2024

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2021

Collaborators (3)

Felix Julius Krendl

Medical University of Innsbruck

AUSTRIA

View details

Rupert Oberhuber

Medical University of Innsbruck

AUSTRIA

View details

Christian Mayr

Landeskrankenhaus Salzburg - Universitätsklinikum der Paracelsus Medizinischen Privatuniversität

AUSTRIA

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Matthias Ocker

Research Interests

Explore related searches

Contact this professor

About

Articles (11)

The importance of preclinical models for cholangiocarcinoma drug discovery

The efficacy of ferroptosis-inducing compounds IKE and RSL3 correlates with the expression of ferroptotic pathway regulators CD71 and SLC7A11 in biliary tract cancer cells

Enhancing anti-CD274 (PD-L1) targeting through combinatorial immunotherapy with bispecific antibodies and fusion proteins: from preclinical to phase II clinical trials

Enhanced Antitumor Efficacy of Radium-223 and Enzalutamide in the Intratibial LNCaP Prostate Cancer Model

Patient Selection Approaches in FGFR Inhibitor Trials—Many Paths to the Same End?

Patient Selection Approaches in FGFR Inhibitor Trials-Many Paths to the Same End?

Ferroptosis in Hepatocellular Carcinoma: Mechanisms, Drug Targets and Approaches to Clinical Translation

Ferroptosis in Hepatocellular Carcinoma: Mechanisms, Drug Targets and Approaches to Clinical Translation

Chemoresistance and resistance to targeted therapies in biliary tract cancer: what have we learned?

Pharmacologic Antagonization of Cannabinoid Receptor 1 Improves Cholestasis in <i>Abcb4</i><SUP>-/-</SUP> Mice

Immunmodulatory Treatment Strategies of Hepatocellular Carcinoma: From Checkpoint Inhibitors Now to an Integrated Approach in the Future

Collaborators (3)

Felix Julius Krendl

Rupert Oberhuber

Christian Mayr

Make your next move.